The degree of matching at HLA-DPB1 predicts for acute graft-versus-host disease and disease relapse following haematopoietic stem cell transplantation.
The importance of matching for HLA-DPB1 in unrelated donor haematopoietic stem cell (HSC) transplantation is little understood. Most transplant centres do not, currently, prospectively match for DPB1, but emerging data show that DPB1 matching does play a role in determining outcome. We studied the impact of HLA-DPB1 matching on outcome in 143 recipients of T-cell depletion transplants, who matched with their respective unrelated donors (allelic level) at HLA-A, -B, -C, -DRB1 and -DQB1. Of those matched at DPB1, 47.2% (17/36) developed acute graft-versus-host disease (aGvHD) as compared to 66.3% (55/83) of those who were mismatched. This led to a 19.1% (95% CI 0.1-38.3%) increase in the chance of developing aGvHD in mismatched patients (P=0.049). Relapse of the original disease occurred in 51 recipients; 23 of 37 (62%) matched at both DPB1 alleles, 28 of 82 (34%) were mismatched at one or two DPB1 alleles. Thus, there was a significantly higher relapse rate (P=0.0011) in transplant recipients who matched at both DPB1 alleles. In conclusion, a donor/recipient DPB1 match was associated with a significantly lower incidence of aGvHD and a significantly higher incidence of disease relapse. This study provides further evidence for an immunogenic role of HLA-DPB1 in HSC transplants.
Shaw
B E
BE
Anthony Nolan Research Institute, Royal Free Hospital, London, UK.
Potter
M N
MN
Mayor
N P
NP
Pay
A L
AL
Smith
C
C
Goldman
J M
JM
Prentice
H Grant
HG
Marsh
S G E
SG
Madrigal
J A
JA
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000453:epidemiology; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology* / Q000401:mortality; D006682:HLA-DP Antigens / Q000276:immunology*; D059868:HLA-DP beta-Chains; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D006650:Histocompatibility Testing / Q000379:methods*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000401:mortality / Q000628:therapy; D008212:Lymphocyte Depletion / Q000379:methods; D008297:Male; D008875:Middle Aged; D010298:Parity; D011237:Predictive Value of Tests; D011336:Probability; D012008:Recurrence; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors
D006682:HLA-DP Antigens; D059868:HLA-DP beta-Chains; C071170:HLA-DPB1 antigen